This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery | MicrobiomeTrials
← Back to trials NCT04918173
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery Recruiting PHASE3 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-07-01Est. Completion: 2026-12-01
Enrollment target: 38 participantsLocations Georgetown University, Washington D.C., District of Columbia, United States University of Miami, Miami, Florida, United States Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States Weill Cornell Medicine, New York, New York, United States Duke University, Durham, North Carolina, United States Yeolyan Hematology and Oncology Centre, Yerevan, Armenia Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie und Hämostaseologie, Vienna, Austria Centre for Thrombosis and Haemaostasis, Nymburk, Czechia Centre de Référence de l'Hémophilie Unité d'Hémostase Clinique Hôpital Cardiologique Louis Pradel, Bron, France University Hospital of Reims, Reims, France Centre Hospitalier Universitaire de Rouen (CHU de Rouen) - Centre de Traitement des Maladies Hemorragiques (CRTH) (Centre d'Hemophiles), Rouen, France Aversi Clinic, Tbilisi, Georgia Klinik fur Angiologie Hamostaseologie Haus 12 A Gerinnungssprechstunde, Berlin, Germany UKB Bonn Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany Other microbiome trials you might be interested in Acquired Antithrombin Deficiency
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in r…
Stanford, United States Est. completion Mar 2028
Pregnancy Complications Pre-Eclampsia Growth Retardation, Intrauterine
Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies …
Nîmes, France Est. completion May 1, 2028
Gerinnungszentrum Rhein-Ruhr, Duisburg, Germany
University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary
Rabin Medical Centre, Institute of Haematology, Petah Tikva, Israel
Sheba Medical Centre, Ramat Gan, Israel
Unita Strutturale Complessa di Immunoematologia e Medicina Trasfusionale -Dipartimento Interaziendale di Medicina Trasfusionale ed Ematologia - ASST Papa Giovanni XXIII ematologia Piazza OMS, 1, Bergamo, Italy
Universita degli Studi di Milano - IRCCS Ospedale Maggiore Policlinico - Centro Emofilia e Trombosi Angelo Bianchi Bonomi, Milan, Italy
University of Padua Medical School, Padua, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy
Emergency County Hospital Craiova, Craiova, Romania
Clinical Center of Serbia, Belgrade, Serbia
Central University Hospital of Asturias, Oviedo, Principality of Asturias, Spain
Hospital Universitario La Paz, Madrid, Spain
Hospital Universitario Morales Meseguer, Murcia, Spain
Ourense University Hospital, Ourense, Spain
Royal-free Hospital-Katherine Dormandy Haemophilia and Thrombosis Centre, London, United Kingdom
St. Thomas Hospital, London, United Kingdom